In a bid to broaden its rare disease franchise, Sanofi has entered into an exclusive license and collaboration agreement with miRecule to develop and commercialise an antibody-RNA conjugate, by combining the latter’s anti-DUX4 RNA therapy with Sanofi’s targeted NANOBODY technology, to treat patients suffering with facioscapulohumeral muscular dystrophy (FSHD). As per the deal, which is worth up to US$400M, Sanofi will gain access to intellectual property rights to miRecule’s FSHD therapy. The companies will together conduct research activities for lead candidate selection, after which Sanofi will pick up responsibility for the programme’s clinical development and commercialisation.